vs
Side-by-side financial comparison of BingEx Ltd (FLX) and IOVANCE BIOTHERAPEUTICS, INC. (IOVA). Click either name above to swap in a different company.
BingEx Ltd is the larger business by last-quarter revenue ($143.2M vs $86.8M, roughly 1.7× IOVANCE BIOTHERAPEUTICS, INC.).
Iovance Biotherapeutics, Inc. is a biopharmaceutical startup based in San Carlos, California. The company works to develop tumor-infiltrating lymphocyte (TIL) therapies against cancer.
FLX vs IOVA — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $143.2M | $86.8M |
| Net Profit | $3.2M | — |
| Gross Margin | 10.8% | 67.4% |
| Operating Margin | — | -84.7% |
| Net Margin | 2.2% | — |
| Revenue YoY | — | 17.7% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $143.2M | — | ||
| Q4 25 | — | $86.8M | ||
| Q3 25 | $141.2M | $67.5M | ||
| Q2 25 | $143.0M | $60.0M | ||
| Q1 25 | $141.0M | $49.3M | ||
| Q4 24 | — | $73.7M | ||
| Q3 24 | $164.6M | $58.6M | ||
| Q2 24 | — | $31.1M |
| Q1 26 | $3.2M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $6.1M | $-91.3M | ||
| Q2 25 | $7.5M | $-111.7M | ||
| Q1 25 | $27.6M | $-116.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | $3.4M | $-83.5M | ||
| Q2 24 | — | $-97.1M |
| Q1 26 | 10.8% | — | ||
| Q4 25 | — | 67.4% | ||
| Q3 25 | 11.1% | 43.0% | ||
| Q2 25 | 12.0% | 5.5% | ||
| Q1 25 | 10.0% | -0.8% | ||
| Q4 24 | — | 68.7% | ||
| Q3 24 | 11.3% | 46.2% | ||
| Q2 24 | — | -0.8% |
| Q1 26 | — | — | ||
| Q4 25 | — | -84.7% | ||
| Q3 25 | 1.4% | -140.7% | ||
| Q2 25 | 1.9% | -189.8% | ||
| Q1 25 | — | -245.8% | ||
| Q4 24 | — | -117.5% | ||
| Q3 24 | 4.0% | -152.1% | ||
| Q2 24 | — | -327.6% |
| Q1 26 | 2.2% | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 4.4% | -135.3% | ||
| Q2 25 | 5.2% | -186.2% | ||
| Q1 25 | 19.6% | -235.5% | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.1% | -142.7% | ||
| Q2 24 | — | -312.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-0.33 | ||
| Q1 25 | — | $-0.36 | ||
| Q4 24 | — | $-0.24 | ||
| Q3 24 | — | $-0.28 | ||
| Q2 24 | — | $-0.34 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $561.1M | $297.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | — | $698.6M |
| Total Assets | $1.3B | $913.2M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $561.1M | — | ||
| Q4 25 | — | $297.0M | ||
| Q3 25 | $628.6M | $300.8M | ||
| Q2 25 | $499.4M | $301.2M | ||
| Q1 25 | $592.4M | $359.7M | ||
| Q4 24 | — | $323.8M | ||
| Q3 24 | $517.4M | $397.5M | ||
| Q2 24 | — | $412.5M |
| Q1 26 | — | — | ||
| Q4 25 | — | $698.6M | ||
| Q3 25 | — | $702.3M | ||
| Q2 25 | — | $698.5M | ||
| Q1 25 | — | $767.9M | ||
| Q4 24 | — | $710.4M | ||
| Q3 24 | — | $773.5M | ||
| Q2 24 | — | $768.5M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | — | $913.2M | ||
| Q3 25 | $1.3B | $904.9M | ||
| Q2 25 | $1.2B | $907.4M | ||
| Q1 25 | $1.2B | $966.7M | ||
| Q4 24 | — | $910.4M | ||
| Q3 24 | $926.8M | $991.1M | ||
| Q2 24 | — | $964.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-52.6M |
| Free Cash FlowOCF − Capex | — | $-61.9M |
| FCF MarginFCF / Revenue | — | -71.3% |
| Capex IntensityCapex / Revenue | — | 10.7% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-336.2M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | — | $-52.6M | ||
| Q3 25 | — | $-78.7M | ||
| Q2 25 | — | $-67.4M | ||
| Q1 25 | — | $-103.7M | ||
| Q4 24 | — | $-73.3M | ||
| Q3 24 | — | $-59.0M | ||
| Q2 24 | — | $-98.4M |
| Q1 26 | — | — | ||
| Q4 25 | — | $-61.9M | ||
| Q3 25 | — | $-89.5M | ||
| Q2 25 | — | $-74.9M | ||
| Q1 25 | — | $-109.9M | ||
| Q4 24 | — | $-77.5M | ||
| Q3 24 | — | $-61.3M | ||
| Q2 24 | — | $-98.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | -71.3% | ||
| Q3 25 | — | -132.7% | ||
| Q2 25 | — | -124.9% | ||
| Q1 25 | — | -222.8% | ||
| Q4 24 | — | -105.1% | ||
| Q3 24 | — | -104.6% | ||
| Q2 24 | — | -317.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | 10.7% | ||
| Q3 25 | — | 16.1% | ||
| Q2 25 | — | 12.4% | ||
| Q1 25 | — | 12.6% | ||
| Q4 24 | — | 5.7% | ||
| Q3 24 | — | 3.9% | ||
| Q2 24 | — | 1.4% |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
FLX
Segment breakdown not available.
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
